![](/msletters/assets/coverImage/J000011_cover.jpg)
- P-ISSN 2233-4203
- E-ISSN 2093-8950
Growth hormone (GH)-releasing peptides (GHRPs) and GH secretagogues (GHSs) are listed in the World Anti-Doping Agency (WADA) Prohibited List. In the present study, we developed and validated a method for the simultaneous analysis of seven GHRPs (alexamorelin, GHRP-1, -2, -4, -5, -6, and hexarelin) and three GHSs (anamorelin, ibutamoren, and ipamorelin) in human urine. Method validation was performed at minimum required performance levels specified by WADA technical documents (2 ng/mL) for all substances, and the method was validated with regard to selectivity (no interference), linearity (R2 > 0.9986), matrix effects (50.0%-141.2%), recovery (10.4%-100.8%), and intra- (2.8%-16.5%) and inter-day (7.0%-22.6%) precisions. The limits of detection for screening and confirmation were 0.05-0.5 ng/mL and 0.05-1 ng/mL, respectively.
Saugy, M.. (2006). . Brit J. Sport Med, 40(Suppl 1), i35-.
Saugy, M.. (1996). . J. Chromatogr. B, 687, 201-.
Baumann, G. P.. (2012). . Endocr. Rev, 33, 155-.
Bowers, C. Y.. (1991). . Endocrinology, 128, 2027-.
Arvat, E.. (2001). . J. Clin. Endocr. Metab, 86, 1169-.
Okano, M.. (2010). . Drug Test Anal, 2, 548-.
Garcia, J. M.. (2009). . Growth Horm. Igf. Res, 19, 267-.
Svensson, J.. (2003). . Growth Horm Igf. Res, 13, 1-.
Thomas, A.. (2011). . Anal. Bioanal. Chem, 401, 507-.
Okano, M.. (2010). . Rapid Commun. Mass Spectrom, 24, 2046-.
Thomas, A.. (2012). . Anal. Chem, 84, 10252-.
Sobolevsky, T.. (2014). . Drug Test Anal, 6, 1087-.
Mazzarino, M.. (2015). . Forensic Toxicol, 33, 321-.
World Anti-Doping Agency. (2015). Technical Document for minimum required performance levels. https://www.wada-ama.org/en/resources/science-medicine/td2015-mrpl.